Work

Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a89

Authors: Sharad Ghamande, Chia-Chi Lin, Daniel C. Cho, Teresa Coleman, Imran Chaudhary, Geoffrey I. Shapiro, Michael Silverman, Min-Wen Kuo, Wendy B. Mach, Yunlong Tseng, Min-Hsiung Kao, Shu Chi Hsu, Sanjay Goel

Institutions: Augusta University Health, National Taiwan University Hospital, Beth Israel Deaconess Medical Center, Montefiore Medical Center, Taiwan Liposome Company, Ltd. (Taiwan)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1978760070

Cites:

Cited by: 4

Related to: 10